Specialist Players Gilead and Novo Nordisk Will Experience Strongest Growth among Leading Pharma Companies between 2010 an

GlaxoSmithKline Bucks Declining Sales Trend Among Top 10 Pharma Companies with Growth over Forecast Period, According to New Analysis from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, of the leading biopharmaceutical companies, specialist players Gilead and Novo Nordisk will experience the strongest growth between 2010 and 2017. Compared to a compound annual growth rate (CAGR) of 2.2 percent for the industry as a whole during this period, Gilead and Novo Nordisk will have CAGRs of 5.2 percent and 5.7 percent, respectively. According to analysis from Decision Resources’ Pharmaview, with a 5.7 percent CAGR through 2017, Novo Nordisk will experience the highest growth rate of the leading biopharmaceutical companies. Novo Nordisk is currently ranked 17 in Pharmaview’s rankings for 2010 but will propel to number 11 in 2017.

“We expect Gilead’s performance over the next seven years to be driven by its HIV franchise, while Novo Nordisk’s strong presence in diabetes will be a key driver of its growth as the disease is taking on epidemic proportions in many countries, fueling increased sales of diabetes therapies over the next several years,” said Decision Resources’ Pharmaview Director Alasdair Milton, Ph.D. “While these specialty players will see a boost over our forecast period, not all will fare as well. Forest, for example, will experience a significant decline in its top-line when Lexapro and Namenda lose patent protection. Although the company has recently attempted to diversify from its core central nervous system franchise, we believe these efforts may have come too late to plug the revenue gap from generic entry.”

The analysis finds that the majority of the current top 10 pharmaceutical companies will also see declining sales over the forecast period, as patents on key products such as Pfizer’s Lipitor begin to expire. Yet, despite declining sales, Pfizer will retain its number one ranking in 2017, as the Wyeth acquisition helps fill the gap left by Lipitor. However, GlaxoSmithKline, bucking the declining sales trend with a CAGR of 1.7 percent from 2010 to 2017, will move from the fifth largest biopharmaceutical company in 2010 to the number two spot behind Pfizer in 2017.

“GlaxoSmithKline is well-positioned for growth, and its movement up the top 10 pharmaceutical company rankings in 2017 will be in part because the company experienced its patent cliff much earlier than its peers, particularly in the United States. The company has also used a number of business development tools, including bolt-on acquisitions, in-licensing and collaborations to build a well-stocked pipeline that we feel will deliver significant returns throughout our forecast period,” added Dr. Milton.

2011 Executive’s Guide Now Available

These findings are from The Executive’s Guide, which is offered with the Pharmaview suite. The Guide provides a succinct overview of the key issues and challenges facing each of the leading biopharmaceutical companies, and the industry as a whole. Updated annually, this high-value resource also offers analysis on key trends within each of the 14 therapeutic areas covered by Pharmaview. Members of the media interested in receiving a copy of the Executive’s Guide should contact Lisa Osgood at [email protected].

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.